Florida Drug-Related Deaths Fall 19%, Fentanyl Deaths Down 46%, New State Report Shows

Drug-related deaths in Florida fell by 19 percent statewide over the most recent reporting period, according to a new report released by the Florida Medical Examiner's Commission on May 13, 2026. The data also shows that opioid-related deaths declined by 42 percent and that deaths specifically attributable to fentanyl, the synthetic opioid at the center of the national overdose epidemic, plummeted by 46 percent. Governor Ron DeSantis highlighted the findings at a press conference in Titusville, calling the results a reflection of sustained law enforcement pressure, expanded treatment access, and state-level policy changes targeting illicit drug trafficking.

The Numbers in Detail

The Medical Examiner's Commission report, which draws on data collected by the state's 24 medical examiner districts, represents a comprehensive accounting of drug-involved deaths across all 67 Florida counties. The 19 percent overall decline marks the largest single-year percentage reduction in drug-related deaths that Florida has recorded since the current data collection methodology was implemented.

Among the specific findings, opioid deaths as a category fell 42 percent, driven primarily by the dramatic drop in fentanyl fatalities. Fentanyl and its analogs have been the dominant driver of overdose deaths nationally and in Florida since roughly 2019, surpassing heroin, prescription opioids, and other drugs as the leading substance in fatal overdoses. The 46 percent reduction in fentanyl-related deaths is particularly significant because fentanyl's extreme potency, it is estimated to be 50 to 100 times more potent than morphine, means that even small quantities can be lethal.

The report also noted declines in deaths involving methamphetamine and cocaine, though those substances continued to appear in a significant share of total drug-related fatalities. Co-involvement of multiple substances remains common in Florida overdose deaths, with many fatalities involving combinations of opioids and stimulants.

What State Officials Attribute the Decline To

Governor DeSantis and the Florida Department of Law Enforcement credited several overlapping factors for the improvement in the overdose statistics. Law enforcement agencies across the state have made seizures of fentanyl and fentanyl analogs a priority, and the sheer volume of drug seizures in recent years has disrupted supply chains that feed the illicit retail market.

The Florida Department of Law Enforcement Commissioner Mark Glass, who appeared alongside the governor at the Titusville event, pointed to joint operations with federal partners including the Drug Enforcement Administration and the Department of Homeland Security as central to the enforcement effort. Fentanyl primarily enters the United States across the southern border and through international mail and package facilities, and interdiction efforts at both the federal and state level have targeted those supply routes.

The expanded availability of naloxone, the opioid reversal medication also known by the brand name Narcan, was also cited as a factor in reducing fatal outcomes from overdose events. Florida law allows pharmacists to dispense naloxone without a prescription, and the state has supported community-based distribution programs that place the medication in the hands of individuals at risk and their families. When administered promptly after a fentanyl overdose, naloxone can reverse the respiratory depression that causes death.

The Role of Treatment Expansion

State officials have also pointed to expanded access to medication-assisted treatment, including buprenorphine and methadone, as contributing to both reduced overdose deaths and reduced relapse rates among individuals in recovery. The Florida Department of Children and Families has supported the expansion of outpatient treatment capacity in counties that historically had limited access to certified treatment providers.

Rural counties in North Florida and the Panhandle region, which faced some of the steepest per capita overdose death rates during the height of the fentanyl epidemic, have seen particular attention in the expansion of treatment services. Telehealth regulations that were relaxed during the pandemic and subsequently made permanent in Florida law have allowed residents in remote areas to access medication-assisted treatment through virtual appointments with certified prescribers.

The Florida Substance Abuse and Mental Health Corporation, a nonprofit that coordinates state-funded substance abuse treatment services, reported increases in both the number of individuals enrolled in treatment programs and the rate of successful completion over the past year. Officials cautioned that success in treatment does not always translate immediately into reduced overdose deaths, given the delayed lag between policy interventions and measurable mortality outcomes.

Florida in the National Context

Florida's progress in reducing drug-related deaths comes as national overdose statistics have also shown signs of improvement following several years of record-high death tolls. The Centers for Disease Control and Prevention reported a decline in national overdose deaths during the most recent reporting period as well, driven by similar reductions in fentanyl-related fatalities, though the national numbers remain at historically elevated levels.

Public health experts nationally have attributed the beginning of a downward trend to a combination of expanded naloxone access, increased treatment availability, shifting drug supply dynamics, and the saturation of enforcement pressure on fentanyl trafficking networks. Florida's results are consistent with and, in some metrics, outpace the national trend, which state officials have cited as evidence that their approach is working.

Florida's experience with the opioid epidemic over the past decade has been shaped significantly by its early role as a destination for so-called pill mills, clinics that prescribed opioid painkillers with minimal medical oversight, which drove prescription opioid addiction rates before the state enacted prescription drug monitoring laws and cracked down on those operations. The subsequent pivot of the drug supply toward heroin and then fentanyl mirrored national patterns but was particularly acute in Florida given the preexisting opioid-dependent population.

Remaining Challenges

Despite the encouraging data, officials and public health advocates cautioned against interpreting the one-year decline as a resolution of the overdose crisis. Drug-related deaths in Florida remain far above the levels seen before the onset of the fentanyl era, and the populations most at risk, including individuals experiencing homelessness, those cycling through the criminal justice system, and people with co-occurring mental health conditions, continue to face significant barriers to treatment access and stable recovery.

Xylazine, a veterinary sedative that has no approved use in humans but has appeared increasingly in illicit drug supplies across the country, has begun to show up in Florida overdose toxicology reports. Xylazine complicates overdose response because it does not respond to naloxone in the same way that opioids do, raising concerns among harm reduction advocates about the adequacy of current reversal strategies if xylazine continues to penetrate the state's drug supply.

State officials acknowledged the emerging xylazine concern and indicated that monitoring and response strategies are being developed. The Florida Department of Health has been in contact with federal agencies and peer state health departments that have dealt with xylazine more extensively to share data and response protocols.

What is Next

The Florida Medical Examiner's Commission will continue issuing quarterly reports on drug-related deaths, with the next report expected in the summer of 2026. Law enforcement agencies across the state have indicated that fentanyl interdiction will remain a top priority through the remainder of the year, and state officials have signaled continued support for naloxone distribution and treatment expansion programs.

Governor DeSantis and the Florida Department of Law Enforcement have set an explicit goal of further reducing drug-related deaths in the coming year, though officials stopped short of specifying a numerical target. The continued downward trajectory in the data will be closely watched by both health advocates and law enforcement as a signal of whether the interventions implemented over the past several years are producing durable change or whether the current reduction reflects factors that may not persist.